Tag Archive for: CD3

QL535: CD2-Based PSMA T-Cell Engager Maintains Anti-Tumor Activity in Advanced Prostate Cancer Models

PSMA-targeted T-cell engagers have struggled in solid tumors because they don’t activate T cells strongly enough and the immune cells become exhausted quickly. QL535 solves this problem by adding a second co-stimulatory signal through CD2, a molecule on T cells that’s abundant in prostate cancer tumors. Researchers analyzed immune cells from 14 advanced prostate cancer […]

New Xaluritamig (AMG 509) Monotherapy Phase 1 Trial for mCRPC

Xaluritamig (AMG 509) represents a promising new immunotherapy option for men with metastatic castration-resistant prostate cancer, or mCRPC, through this  new Phase 1 trial. The study aims to evaluate the safety profile of xaluritamig administered as monotherapy (plus ADT, as usual) at a specific proposed regimen in adult male participants whose cancer has progressed despite […]

QLS2401: A Trispecific PSMA/STEAP1/CD3 T‑Cell Engager for mCRPC

QLS2401 is a trispecific T‑cell engager designed for metastatic castration‑resistant prostate cancer (mCRPC). It binds three targets at once: PSMA and STEAP1 on tumor cells, plus CD3 on T cells. This design allows it to physically connect a patient’s T cells to prostate‑cancer cells, triggering T‑cell activation and killing of the tumor. Both PSMA and […]

HLX3902: A Trispecific T‑Cell Engager Rewiring the Immune Desert in Prostate Cancer

HLX3902 is a STEAP1×CD3×CD28 trispecific T‑cell engager developed as a potential first‑in‑class immunotherapy for prostate cancer. Prostate tumors are largely “cold” from an immunological standpoint. The microenvironment is immunosuppressive, T cells are scarce inside the tumor mass, and those that do infiltrate often burn out quickly after activation. Classical CD3‑only bispecific TCEs can force T […]

HER2 FPBMC Therapy in the AM006 Phase 1/2 Trial for Metastatic Prostate Cancer

The AM006 clinical trial, tests HER2 FPBMC anti-CD3 x anti-HER2 bispecific antibody (HER2Bi)-armed activated T cells, in patients with HER2-positive metastatic prostate and breast cancer. For prostate cancer patients, this targets the 20-30% of metastatic cases overexpressing HER2, offering a fresh immune-based option after standard therapies fail. HER2 FPBMC starts with a simple blood draw […]